A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
Public ClinicalTrials.gov record NCT06073119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.
Study identification
- NCT ID
- NCT06073119
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 221 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2023
- Primary completion
- Nov 12, 2024
- Completion
- Dec 10, 2024
- Last update posted
- Nov 9, 2025
2023 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Clinical Trials Site Number : 8400025 | Scottsdale | Arizona | 85260 | — |
| Dermatology Research Associates- Site Number : 8400019 | Los Angeles | California | 90045 | — |
| Daxia Trials Site Number : 8400022 | Boca Raton | Florida | 33431 | — |
| Renaissance Research and Medical Group, Inc- Site Number : 8400018 | Cape Coral | Florida | 33991 | — |
| Driven Research, LLC- Site Number : 8400012 | Coral Gables | Florida | 33134 | — |
| FXM Clinical Research Ft. Lauderdale, LLC Site Number : 8400015 | Fort Lauderdale | Florida | 33308 | — |
| Direct Helpers Medical Center Inc- Site Number : 8400023 | Hialeah | Florida | 33012 | — |
| FXM Clinical Research Miami, LLC- Site Number : 8400016 | Miami | Florida | 33175 | — |
| Center for Clinical Studies, LTD. LLP- Site Number : 8400007 | Houston | Texas | 77004 | — |
| Center for Clinical Studies, LTD, LLP- Site Number : 8400013 | Webster | Texas | 77598 | — |
| Jordan Valley Dermatology Center- Site Number : 8400027 | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06073119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06073119 live on ClinicalTrials.gov.